Group Cancer Cover Above a Rs 3 to 5 Lakh GMC Base: What Drop-Down Oncology Cover Buys That a Super Top-Up Does Not

In July 2026, Howden India brought to market a group cancer cover built specifically for employer-sponsored health plans. Reported by The Times of India on 30 July 2026, Howden India CEO Amit Agarwal said the firm worked for almost a year with insurers to build the product, and that discussions with another 10 to 12 employers are in the pipeline.

The problem the product addresses is arithmetic, not exotic. As Agarwal put it: "although cancer-related treatment is covered under your GMC policy, the insurance limits are pretty less. On average, Indian corporates buy anywhere between Rs 3 lakh to Rs 5 lakh", and those limits were not enough. A group mediclaim base of Rs 3 to 5 lakh per employee is sized for the median hospitalisation, a surgery, a delivery, an infection. A cancer diagnosis is a different claim shape entirely: treatment runs across months or years, in repeated cycles, often combining surgery, radiation and drug therapy, and newer drug regimens are priced per cycle rather than per admission. The base sum insured does not fail on the first bill. It fails somewhere in the middle of treatment, which is the worst possible point for the employee and the most visible possible failure for the HR team that bought the plan.

The launch also sits inside a wider shift in how employers spend on benefits. Agarwal's framing in the same report: "If you have 100 employees, only about 9 or 10 will use this medical facility. Whereas OPD would actually be utilised by 50-60% of your population in a year. A lot of these companies are investing heavily in OPD." Employers are differentiating benefits spend by how it is actually consumed, and a cancer layer is the mirror image of the OPD trend: low frequency, extreme severity, exactly the exposure an insurance structure rather than a spending benefit should carry.

The reported design does three distinct things, and the differences between them are the whole point of the product.

First, it behaves as an excess layer: it meets expenses once the underlying group health policy is exhausted. On a cancer claim that has burned through a Rs 4 lakh base, the cancer cover continues paying. This part looks like a super top-up restricted to one disease, and on its own it would not justify a new product category.

Second, it pays for certain cancer treatments not covered under the base policy. This is where it departs from a top-up. A conventional top-up indemnifies the same kind of expense as the base, just higher up. This cover extends the scope of what is payable, not only the amount.

Third, and most unusually, where the base GMC excludes a treatment, in Agarwal's words, "this policy will drop down as well and cover you from ground up." A drop-down means the attachment point collapses for that claim: the cancer policy does not wait for the base to pay its Rs 3 to 5 lakh first, because the base was never going to pay anything for an excluded treatment. The cancer cover steps into the base layer's position and pays from the first rupee.

How the policy wording defines each trigger, what counts as exhaustion, which treatments sit on the extended-scope list, and what precisely activates the drop-down, is where the product will be won or lost at claim time. Those questions are set out in the final section.

The reported cover includes employees with pre-existing diseases, and the reason given is structural: it is built in a corporate construct. That phrase carries real underwriting content.

Retail cancer and critical illness products are individually underwritten. An applicant with a prior malignancy, or often even a strong family history, is declined, loaded, or accepted with the condition excluded, and waiting periods apply before full cover attaches. The insurer prices each life because each life chose to buy, and the people most likely to buy are the people most likely to claim.

A group placement inverts the selection problem. Nobody in the workforce chose to be covered; the employer covered everyone. The insurer prices the pool, not the person, which is the same logic that lets a standard group health policy cover pre-existing conditions from day one while retail health imposes multi-year waiting periods. Writing cancer cover into that construct means an employee who has already had cancer, or is currently in treatment, is inside the cover rather than carved out of it.

For an employer, this is arguably the strongest argument for the group route over asking employees to buy retail cancer policies themselves. The employees who most need the cover, those with a history or an active diagnosis, are exactly the ones the retail market will not take on acceptable terms. It is also the feature that makes the pricing question hard, which is why the final section treats the product's unproven claims experience as a live issue rather than a footnote.

The bluntest response to an inadequate base is to raise it: move the plan from Rs 3 lakh to Rs 10 lakh per family and the median cancer claim fits inside the base again. Some employers should do exactly this, particularly those whose base is low against their sector's norms. But the cost mechanics deserve a clear-eyed look.

Raising the base sum insured raises the ceiling for every claim type, not just oncology. Every hospitalisation across the whole population now settles against a higher limit, and the premium moves with the whole book's expected burn, not with the cancer tail alone. In a market where group health premiums are already hardening under medical inflation, a two- or three-fold increase in base sum insured is an expensive way to solve a problem that sits in a handful of severe claims a year.

There is also a renewal-dynamics consequence. Group health is experience rated: this year's claims ratio is next year's negotiation. Concentrating all cover in one base layer means the occasional Rs 20 lakh oncology claim lands directly in the base policy's burn and drives the renewal for the entire plan. Structuring severity into a separate layer, whether a super top-up or a cancer cover, quarantines the tail so that a bad cancer year does not automatically reprice the whole base.

And a higher base still shares the base policy's scope. If a treatment is excluded at Rs 3 lakh, it is equally excluded at Rs 10 lakh. Raising the sum insured answers the adequacy problem for covered treatments and does nothing for excluded ones.

The established instrument for the adequacy problem is the group super top-up: a policy with an aggregate deductible typically set equal to the base sum insured, paying indemnity above it. Once a family's admissible expenses in a policy year cross the deductible, the top-up pays, regardless of whether one large claim or several smaller ones did the eroding. Because the insurer only ever pays above the deductible, the premium per lakh of cover is a fraction of base-layer pricing, which is why a super top-up is the standard advice in any group health programme design.

Against a cancer claim, the super top-up does its core job: the long, expensive treatment exhausts the base and the top-up continues paying. For pure limit inadequacy on covered treatments, it remains the cheapest fix available, and it covers severity from every cause, an accident, a cardiac event, a transplant, not oncology alone. That breadth is a genuine advantage over a single-disease layer.

What it cannot do is escape the base policy's scope. A super top-up pays admissible expenses above the deductible, and admissibility is defined by its own wording, which in group placements typically tracks the base policy's exclusions or applies a similar standard exclusion list. Three consequences follow. A treatment the base excludes usually does not erode the deductible, so the family is further from the top-up attaching, not closer. The same treatment is typically inadmissible under the top-up itself, so nothing is payable above the deductible either. And there is no drop-down: no mechanism exists by which the top-up steps into the base layer and pays from the ground up.

So the honest comparison is this: a super top-up solves "the limit was too small" more cheaply and more broadly than a cancer cover does. It leaves "the treatment was not covered" entirely unsolved, and that second failure mode is precisely where modern oncology, with its newer drug therapies and outpatient-delivered regimens, generates the disputes.

The third instrument already on most brokers' shelves is group critical illness (CI) cover: a benefit policy that pays a fixed lump sum on first diagnosis of a listed condition, cancer of specified severity among them. It is a fundamentally different contract from everything above. GMC, super top-ups and the cancer cover are indemnity products that reimburse actual treatment expense; CI pays a defined amount on a defined event and is indifferent to what treatment costs or whether any treatment happens at all.

That difference cuts both ways. The lump sum arrives near the start of the illness and can be spent on anything: income replacement during unpaid leave, travel to a treatment centre, household support, or treatments no indemnity policy would touch. No bills, no network, no expense-by-expense adjudication. For the family's finances as a whole, rather than the hospital invoice specifically, CI is often the more useful rupee.

But a lump sum does not scale with treatment cost. A Rs 10 lakh CI payout is generous against a Rs 6 lakh treatment and hopeless against a Rs 40 lakh one; an indemnity layer tracks the actual bill up to its limit. CI definitions also gate the benefit by severity and stage: group CI wordings commonly pay on major-stage cancer and exclude or pay a reduced percentage on early-stage and in-situ disease, so a diagnosis that triggers enormous treatment expense may trigger no CI payment. And once the lump sum is paid, the cover for that condition is spent, however long treatment continues.

The practical conclusion is that CI is a complement, not a substitute. It solves the non-medical costs of a severe diagnosis, which no indemnity product addresses. It does not solve treatment-cost adequacy, and an employer buying CI instead of an excess indemnity layer is answering a different question from the one the Rs 3 to 5 lakh base poses.

The honest caveat comes from the product's own architect. Agarwal said the product would need at least 100 corporate policies and 12 to 24 months of claims experience before its pricing could be assessed. That is not a throwaway line; it defines what an early buyer is actually buying. First-generation pricing is an actuarial estimate on a pool that does not exist yet, covering pre-existing disease in a population nobody has run cancer-specific claims data on. If early experience runs hot, renewals will reprice sharply or wordings will tighten, and an employer that anchored its benefits communication on the cancer layer will absorb that correction in front of its workforce. Buying early is a reasonable decision; assuming year-one pricing is the settled price is not. Employers with the scale to consider self-funded structures should run the same claims-volatility logic on this layer that they run on any new benefit.

Because the pricing is unsettled, the wording is where a first placement is actually negotiated. The questions to put to the broker and insurer before signing:

1. What counts as exhaustion of the base? Per member or per family, per policy year or per illness, and does a claim the base part-paid because of room-rent capping or proportionate deduction count as exhaustion of the balance?
2. Which treatments sit on the extended-scope list? "Certain cancer treatments not covered under the base" is a list, not a principle. Get the list, and ask how treatments approved after policy inception are handled.
3. What precisely triggers the drop-down? A named exclusion in the base wording, a claim rejection in practice, or the insurer's own assessment? Who decides, and within what timeline, when the base insurer and the cancer insurer disagree?
4. How is pre-existing disease defined and evidenced? Day-one inclusion for declared conditions, undeclared conditions, and employees mid-treatment at inception are three different underwriting positions.
5. What happens at the edges of employment? Continuity for an employee diagnosed while covered who then exits, cover for dependants, and treatment of members added mid-term.
6. How does it coordinate with an existing super top-up? Order of payment, whether cancer-cover payments erode the top-up deductible, and which policy is primary for a covered-but-exhausted claim.

Comparing these answers across insurers requires the wordings themselves, not the quote summaries. Sarvada gives commercial-insurance brokers and corporate benefits teams searchable access to insurer group health, top-up and benefit wordings and the intelligence around them, so exhaustion clauses, exclusion lists and drop-down triggers can be compared line by line before a placement is signed. Teams evaluating a cancer layer against a super top-up can Request Access to run that comparison.